Maite Verreault
Overview
Explore the profile of Maite Verreault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khuu A, Verreault M, Colin P, Tran H, Idbaih A
Cells
. 2024 Nov;
13(22).
PMID: 39594617
Antisense oligonucleotides (ASOs) are promising drugs capable of modulating the protein expression of virtually any target with high specificity and high affinity through complementary base pairing. However, this requires a...
2.
Fabro F, Kers T, Feller K, Beerens C, Ntafoulis I, Idbaih A, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958662
Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma. Despite treatment, prognosis is still poor largely due to the emergence of temozolomide resistance. This resistance is closely linked...
3.
Bruschi M, Midjek L, Ajlil Y, Vairy S, Lancien M, Ghermaoui S, et al.
Neuro Oncol
. 2023 Sep;
26(3):553-568.
PMID: 37702430
Background: Diffuse midline gliomas (DMG) are pediatric tumors with negligible 2-year survival after diagnosis characterized by their ability to infiltrate the central nervous system. In the hope of controlling the...
4.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, et al.
Br J Cancer
. 2023 Aug;
129(8):1327-1338.
PMID: 37620410
Background: Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of in situ microenvironment affects the clinically-predictive value of...
5.
Maucort C, Bonnet M, Ortuno J, Tucker G, Quissac E, Verreault M, et al.
J Med Chem
. 2023 Jul;
66(15):10639-10657.
PMID: 37449818
Noncoding RNAs (ncRNAs) play pivotal roles in the regulation of gene expression and represent a promising target for the development of new therapeutic approaches. Among these ncRNAs, microRNAs (miRNAs or...
6.
Biswas A, Salvucci M, Connor K, Dussmann H, Carberry S, Fichtner M, et al.
J Neurooncol
. 2023 May;
163(2):327-338.
PMID: 37237151
Background: Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for...
7.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2023 Mar;
9(8):692.
PMID: 36997420
No abstract available.
8.
Hasyeoui M, Lassagne F, Erb W, Nael M, Elokely K, Chaikuad A, et al.
Bioorg Chem
. 2023 Mar;
134:106456.
PMID: 36913879
The 2-(3-pyridyl)oxazolo[5,4-f]quinoxalines CD-07 and FL-291 are ATP-competitive GSK-3 kinase inhibitors. Here, we investigated the impact of FL-291 on neuroblastoma cell viability and showed that treatment at 10 μM (i.e. ∼500...
9.
Ahmed M, Hernandez-Verdin I, Quissac E, Lemaire N, Guerin C, Guyonnet L, et al.
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839777
Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood-brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the...
10.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2022 Nov;
9(1):9-27.
PMID: 36400694
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has been recognized as an...